Litigation Details for Allergan, Inc. v. Sandoz Inc (E.D. Tex. 2011)

Allergan, Inc. v. Sandoz Inc (E.D. Tex. 2011)

Docket		Date Filed	2011-08-26
Court	District Court, E.D. Texas	Date Terminated	2014-01-13
Cause	35:271 Patent Infringement	Assigned To	Michael H. Schneider Sr.
Jury Demand	Both	Referred To
Parties	WATSON LABORATORIES INC
Patents	6,403,649; 7,851,504; 8,278,353; 8,299,118; 8,309,605; 8,338,479
Attorneys	Brian M Kramer
Firms	Johnny Ward , Jr
Link to Docket	External link to docket

Details for Allergan, Inc. v. Sandoz Inc (E.D. Tex. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-08-26				External link to document

Allergan, Inc. v. Sandoz Inc. Litigation Summary: Lumigan 0.01% Patent Dispute

Last updated: August 15, 2026

Allergan, Inc. v. Sandoz Inc., No. 6:11-cv-00441, was a Hatch-Waxman patent case involving Sandoz's abbreviated new drug application for a generic version of Allergan's Lumigan 0.01% ophthalmic solution, whose active ingredient is bimatoprost. The dispute centered on U.S. Patent No. 7,851,504, which claimed methods of treating glaucoma or ocular hypertension with low-concentration bimatoprost while reducing treatment-related adverse effects. The Federal Circuit addressed the case in two decisions, including a 2015 decision that upheld the patent's validity and infringement findings. [1], [2]

The case protected Allergan's U.S. market for Lumigan 0.01% against an ANDA-based generic challenge. The principal legal issue was whether the claimed low-dose treatment regimen would have been obvious in view of earlier bimatoprost formulations and clinical data.

What drug and patents were at issue in Allergan v. Sandoz?

The litigation involved Lumigan 0.01%, an ophthalmic solution containing bimatoprost for reducing elevated intraocular pressure in patients with glaucoma or ocular hypertension.

Item	Details
Branded drug	Lumigan 0.01% ophthalmic solution
Active ingredient	Bimatoprost
Therapeutic category	Glaucoma and ocular-hypertension treatment
Plaintiff	Allergan, Inc.
Defendant	Sandoz Inc.
ANDA challenger	Sandoz
District court	U.S. District Court for the Eastern District of Texas
Case number	6:11-cv-00441
Primary patent	U.S. Patent No. 7,851,504
Federal Circuit decisions	726 F.3d 1286 and 796 F.3d 1293
Regulatory pathway	ANDA with Paragraph IV certification

The '504 patent claimed methods using a 0.01% bimatoprost formulation. The patent distinguished the lower-concentration product from Allergan's earlier 0.03% bimatoprost formulation, which was associated with ocular side effects such as conjunctival hyperemia, or eye redness. [1]

What patents protect Lumigan 0.01%?

The principal patent litigated in this case was U.S. Patent No. 7,851,504, titled "Methods of treating glaucoma with bimatoprost." The patent issued in December 2010 and originated from Allergan's research into reducing adverse effects while maintaining intraocular-pressure-lowering efficacy.

The asserted claims generally required:

1. Treating a patient with glaucoma or ocular hypertension;
2. Administering bimatoprost ophthalmically;
3. Using a concentration of approximately 0.01%; and
4. Achieving a reduction in one or more adverse effects compared with higher-concentration treatment.

The patent was directed to a method of use, rather than merely the chemical structure of bimatoprost. That distinction mattered because bimatoprost itself was known before the patent's filing. Allergan's protection depended on the claimed concentration, treatment method and reduced-side-effect profile.

What formulations were protected?

The protected product was the low-concentration ophthalmic formulation used in Lumigan 0.01%. The case did not establish broad ownership of every bimatoprost ophthalmic product. Its commercial value came from the combination of:

• Bimatoprost as the active pharmaceutical ingredient;
• A 0.01% concentration;
• Topical ophthalmic administration; and
• A claimed reduction in adverse effects relative to higher-dose treatment.

The litigation therefore illustrates the commercial importance of formulation and method-of-use patents after composition-of-matter protection has weakened or expired.

Why did Sandoz file a Paragraph IV challenge?

Sandoz sought FDA approval to market a generic bimatoprost ophthalmic solution through an ANDA. Sandoz certified under Paragraph IV of the Hatch-Waxman Act that the relevant Allergan patent was invalid, unenforceable or would not be infringed by the proposed generic product.

A Paragraph IV certification is treated as an artificial act of infringement under 35 U.S.C. § 271(e)(2). Allergan responded by filing suit within the statutory period, triggering the Hatch-Waxman litigation framework and an automatic FDA approval stay of up to 30 months under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions.

The case was therefore not a conventional post-launch patent dispute. It was designed to determine whether Sandoz could obtain FDA approval and enter the market before the asserted patent's expiration.

What were the main legal issues?

The litigation focused on obviousness, claim construction and infringement.

Was the low-dose bimatoprost method obvious?

Sandoz argued that the claimed 0.01% treatment regimen was an obvious modification of known bimatoprost therapy. The defense relied on prior art concerning:

• Bimatoprost's known efficacy in treating glaucoma;
• Earlier ophthalmic bimatoprost formulations;
• Dose-ranging studies;
• The known relationship between concentration and ocular side effects; and
• Routine experimentation as a way to identify an effective lower concentration.

Allergan argued that the prior art did not provide a sufficient reason to select 0.01% with a reasonable expectation of achieving comparable pressure reduction while reducing side effects. Allergan also relied on clinical evidence and secondary considerations, including unexpected results and commercial success.

The district court found the asserted claims nonobvious. The Federal Circuit ultimately upheld that result. The appellate analysis treated the claimed low-dose regimen as more than a routine optimization because the record supported a meaningful efficacy and tolerability tradeoff at the claimed concentration. [2]

How did claim construction affect the dispute?

The Federal Circuit's 2013 decision addressed claim-construction issues concerning the scope of the claimed treatment method and the relationship between the claimed method and the side-effect limitation. The construction determined whether Sandoz's proposed product and labeled use would fall within the patent claims.

The court's analysis was important because the patent did not claim a new active ingredient. The scope of protection depended on how precisely the court interpreted the method, concentration and clinical-effect limitations. [1]

Did Sandoz infringe?

The district court found that Sandoz's proposed generic product would infringe the asserted claims. The infringement analysis relied heavily on Sandoz's ANDA and proposed labeling. In Hatch-Waxman litigation, the proposed label can establish induced infringement when it directs physicians or patients to use the generic product in a manner covered by the patent.

The Federal Circuit affirmed the relevant infringement judgment. The ruling prevented Sandoz from using an ANDA approval to market the proposed product during the enforceable life of the patent. [2]

What did the Federal Circuit decide?

The Federal Circuit issued decisions associated with the litigation in 2013 and 2015.

2013 Federal Circuit decision

In Allergan, Inc. v. Sandoz Inc., 726 F.3d 1286 (Fed. Cir. 2013), the court addressed the district court's claim construction and related patent issues. The decision clarified the scope of the method claims and remanded or otherwise continued portions of the dispute for further proceedings. [1]

2015 Federal Circuit decision

In Allergan, Inc. v. Sandoz Inc., 796 F.3d 1293 (Fed. Cir. 2015), the Federal Circuit upheld the district court's determination that the asserted claims were not invalid for obviousness and that Sandoz's proposed product infringed. The court credited the evidence that the 0.01% concentration achieved a clinically meaningful reduction in side effects without sacrificing the relevant therapeutic effect. [2]

The result preserved Allergan's patent position against Sandoz's ANDA product. The Federal Circuit decision also reinforced the evidentiary value of clinical data in pharmaceutical obviousness disputes, particularly where a patent claims a specific dosage or concentration rather than a new molecule.

When did Lumigan 0.01% lose patent exclusivity?

The '504 patent issued on December 14, 2010. Based on the patent's statutory term, its nominal expiration was in 2027, subject to patent-term adjustment and any applicable patent-term extension. The patent term reflected the filing history and statutory adjustments rather than a standard 20-year term calculated only from the issue date. [3]

The litigation record is best understood as protecting Lumigan 0.01% during the period when the '504 patent remained enforceable. FDA approval timing, pediatric exclusivity, patent-term adjustment and any settlement terms could affect the first permissible generic launch date.

What was the Orange Book status?

The relevant Lumigan patent was listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. Sandoz's Paragraph IV certification to the listed patent supplied the jurisdictional and procedural basis for the action. [3]

Orange Book status does not itself establish patent validity. It identifies patents submitted by the NDA holder or patent owner as covering the approved drug, its formulation or an approved method of use. The court's judgment determined the enforceability and infringement consequences in this dispute.

Was there a settlement agreement?

The reported Federal Circuit decisions reflect adjudication of the patent dispute and do not identify a publicly reported settlement as the basis for the final appellate outcome. The case should therefore be classified as a litigated Hatch-Waxman matter rather than a settlement-driven generic-entry case. [1], [2]

Any separate commercial agreement, license or launch provision would need to be evaluated from the parties' filings, FTC disclosures or transaction documents. The reported appellate opinions do not establish a broad license granted to Sandoz.

What was the commercial impact on Allergan and Sandoz?

The immediate commercial effect was delayed or restricted U.S. entry for Sandoz's proposed generic bimatoprost 0.01% product.

Allergan's exposure

Lumigan 0.01% was a branded ophthalmic product with value derived from chronic treatment of glaucoma and ocular hypertension. A generic launch would have created:

• Price erosion after generic substitution;
• Loss of prescription volume;
• Reduced formulary leverage;
• Pressure on remaining branded bimatoprost products; and
• Potential spillover effects on Allergan's broader ophthalmology portfolio.

The case did not produce a reported damages award because the dispute arose before commercial launch. The principal economic remedy was exclusion of the proposed ANDA product during the patent term.

Sandoz's exposure

Sandoz faced the cost of patent litigation, delayed approval and the risk that its ANDA would not produce an immediately marketable product. The case also limited the value of Sandoz's formulation and regulatory investment until the patent barriers were removed.

Because bimatoprost was an established active ingredient, the principal barrier was not chemical synthesis. It was the enforceability of the low-dose method-of-use patent and the ability to obtain approval without infringing the listed claims.

How strong was Allergan's patent estate?

The '504 patent was strong against the specific Sandoz challenge but narrower than a composition-of-matter patent.

Strength factor	Assessment
New chemical entity protection	Limited; bimatoprost was previously known
Formulation protection	Meaningful for the 0.01% ophthalmic product
Method-of-use protection	Strong after the Federal Circuit decisions
Clinical evidence	Important support for nonobviousness
ANDA enforcement	Effective because the proposed label supported infringement
Generic design-around potential	Possible if the product or labeling avoided the claimed concentration and use
Geographic reach	Primarily U.S. protection under the asserted U.S. patent
Manufacturing barrier	Moderate; the active ingredient was known, but ophthalmic formulation quality and regulatory compliance remained necessary

The patent's strength came from the combined clinical and legal record. Allergan did not rely solely on the fact that a lower concentration existed. It demonstrated that the claimed regimen produced an unexpected clinical balance between efficacy and tolerability.

What generic launch risks existed after the ruling?

The ruling reduced Sandoz's ability to launch the proposed product under its existing ANDA and label. Generic entry could still arise through several routes:

1. Expiration of the '504 patent;
2. A later invalidity or noninfringement challenge;
3. A redesigned formulation outside the asserted claims;
4. A label that omitted the patented method, if FDA approval remained available; or
5. A license or settlement with Allergan.

A product that used a different concentration, different formulation parameters or a noninfringing label could present a different patent analysis. The ruling did not create perpetual exclusivity for all bimatoprost products.

How does this case compare with biologic and small-molecule exclusivity?

This was a small-molecule Hatch-Waxman case, not a biologic-biosimilar dispute.

Issue	Allergan v. Sandoz	Biologic-biosimilar litigation
FDA pathway	ANDA	BLA and abbreviated biologics pathway
Patent notice	Paragraph IV certification	Biosimilar patent-exchange process
Product	Bimatoprost ophthalmic solution	Biologic medicine
Principal patent risk	Method of use and formulation	Composition, process, formulation and device patents
Automatic approval stay	Hatch-Waxman 30-month framework	Different statutory framework
Substitution	Pharmacy substitution may apply under state law	Interchangeability depends on FDA designation

Biosimilar risk was not directly relevant to the case. The commercial threat was generic substitution for a prescription ophthalmic solution.

Key Takeaways

• Allergan sued Sandoz over an ANDA for generic Lumigan 0.01%, a bimatoprost ophthalmic solution.
• The principal patent was U.S. Patent No. 7,851,504.
• The patent protected a low-concentration bimatoprost treatment method associated with reduced ocular side effects.
• Sandoz mounted a Paragraph IV challenge under the Hatch-Waxman Act.
• The Federal Circuit upheld the patent's validity and the infringement judgment in 2015.
• The ruling delayed Sandoz's proposed generic entry and preserved Allergan's U.S. market protection during the enforceable patent term.
• The case demonstrates the value of clinical evidence supporting dosage and concentration patents when the active ingredient is already known.
• The patent estate was commercially significant but narrower than composition-of-matter protection because competitors could potentially pursue noninfringing formulations or labels.

FAQs

What was the drug in Allergan v. Sandoz 6:11-cv-00441?

The drug was Lumigan 0.01%, an ophthalmic bimatoprost solution used to treat glaucoma and ocular hypertension.

What patent did Allergan assert against Sandoz?

Allergan principally asserted U.S. Patent No. 7,851,504, covering methods of treating glaucoma with low-concentration bimatoprost.

Did the Federal Circuit invalidate Allergan's Lumigan patent?

No. In the reported 2015 decision, the Federal Circuit upheld the relevant validity and infringement findings in Allergan's favor.

Was Sandoz allowed to launch its generic bimatoprost product immediately?

No. The judgment prevented Sandoz from marketing the proposed ANDA product during the enforceable period of the asserted patent, absent a later legal or commercial resolution.

Did Allergan v. Sandoz involve a biosimilar?

No. It involved a small-molecule generic drug under the Hatch-Waxman ANDA framework, not a biosimilar under the Public Health Service Act.

References

1. Allergan, Inc. v. Sandoz Inc., 726 F.3d 1286 (Fed. Cir. 2013).

2. Allergan, Inc. v. Sandoz Inc., 796 F.3d 1293 (Fed. Cir. 2015).

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. U.S. Patent No. 7,851,504. (2010). Methods of treating glaucoma with bimatoprost. U.S. Patent and Trademark Office.